Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults

Journal of Clinical Oncology

Volumn 15, Issue 6, 1997, Pages 2254-2261

  Bow, Eric J ^a   Loewen, Ruth ^a   Cheang, Mary S ^a   Shore, Tsiporah B ^a   Rubinger, Morel ^a   Schacter, Brent ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPTERIN; CISPLATIN; CYTARABINE; FLUOROURACIL; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER REGRESSION; CYTOTOXICITY; DISEASE SEVERITY; FEMALE; HEPATOSPLENOMEGALY; HUMAN; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; MULTIVARIATE ANALYSIS; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL;

EID: 0030906422     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.6.2254     Document Type: Article

References (40)

1. Fromm H, Rodgers JB Jr: Effect of aminopterin on lipid absorption: Depression of lipid reesterifying enzymes. Am J Physiol 221:998-1002, 1971
2. Baskerville A, Batter-Hatton D: Intestinal lesions induced experimentally by methotrexate. Br J Exp Path 58:663-669, 1977
3. Milles SS, Muggia AL, Spiro H: Colonie histologic changes induced by 5-fluorouracil. Gastroenterology 43:391-399, 1962
4. Allan SG, Smyth JF: Small intestinal mucosal toxicity of cis-platinum - Comparison of toxicity with platinum analogues and dexamethasone. Br J Cancer 53:355-360, 1986
5. Slavin RE, Dias MA, Saral R: Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols. Cancer 42:1747-1759, 1978
6. Bochud P-Y, Calandra Th, Franciola P: Bacteremia due to viridans streptococci in neutropenic patients: A review. Am J Med 97:256-264, 1994
7. Kern W, Kurrle E, Schmeiser T: Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy. A review of 55 cases. Infection 18:138-145, 1990
8. Bochud P-Y, Eggiman P, Calandra Th, et al: Bacteremia due to viridans streptococcus in neutropenic patients with cancer: Clinical spectrum and risk factors. Clin Infect Dis 18:25-31, 1995
9. Sotiropoulos SV, Jackson MA, Woods JM: Alpha-streptococcal septicemia in leukemic children treated with continuous or large dose intermittent cytosine arabinoside. Pediatr Infect Dis 8:755-758, 1989
10. Bow EJ, Loewen R, Cheang MS, et al: Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: The pathogenetic role of the anti-leukemic regimen. Clin Infect Dis 21:361-369, 1995
11. 51Cr-labelled EDTA absorption test. Lancet 1:323-325, 1983
12. Hollander D, Vadheim CM. Brettholz E, et al: Increased intestinal permeability in patients with Crohn's disease and their relatives. A possible etiologic factor. Ann Intern Med 105:883-885, 1986
13. Meddings JB, Sutherland LR, Byles NI, et al: Sucrose: A novel permeability marker for gastroduodenal disease. Gastroenterology 104:1619-1626, 1993
14. May GR, Sutherland LR, Meddings JB: Is small intestinal permeability really increased in relatives of patients with Crohn's disease. Gastroenterology 104:1627-1632, 1993
15. Siber GR, Mayer RJ, Levin MJ: Increased gastrointestinal absorption of large molecules in patients after 5-fluorouracil therapy for metastatic colon carcinoma. Cancer Res 40:3430-3436, 1980
16. Kraut JR, Lloyd-Still JD: The 1-hr blood xylose test in the evaluation of malabsorption in infants and children. Am J Clin Nutr 33:2328-2333, 1980
17. Craig RM, Atkinson AJ: D-xylose testing: A review. Gastroenterology 95:223-231, 1988
18. Shaw MT, Spector MH, Ladman AJ: Effects of cancer, radiotherapy and cytotoxic agents on intestinal structure and function. Cancer Treat Rev 6:141-151, 1979
19. Bow EJ, Loewen R, Vaughan D: Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 20:907-912, 1995
20. Bow EJ, Kilpatrick MG, Scott BA, et al: Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high-dose cytarabine post-remission consolidation for myelosuppression, infectious morbidity and outcome. Cancer 74:52-60, 1994
21. Eberts TJ, Sample RHB, Glick MR, et al: A simplified, colormetric micromethod for xylose in serum or urine with phloroglucinol. Clin Chem 25:1440-1443, 1979
22. Reece DE, Barnett M, Bow E, et al: High-dose cytosine arabinoside (HD Ara-C), etoposide (VP-16) and daunorubicin (DNR) as initial induction and consolidation therapy for adult acute myelogenous leukemia (AML). Blood 76:312a. 1990 (suppl 1: abstr 1238)
23. Bow EJ, Sutherland JA, Kilpatrick MG, et al: Therapy of untreated acute myeloid leukemia in the elderly: Remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J Clin Oncol 14:1345-1352, 1996
24. Bow EJ, Gallant G, Williams G, et al: Non-cytarabine (ARA-C)-based induction therapy in adult acute myeloid leukemia (AML) with idarubicin (I), etoposide (E) and carboplatin (C) in Canada. Proc Am Soc Clin Oncol 14:337, 1995 (abstr)
25. Kaplan ER, Meier R: Non-parametric estimation from incompatible observations. J Am Stat Assoc 53:457-481, 1958
26. Cheson BD, Cassileth PA, Head DR, et al: Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990
27. Cox DR: Regression models and life tables. J Royal Stat Soc 34:187-202, 1972
28. Starnes HF, Moore FD, Mentzer, et al: Abdominal pain in neutropenic cancer patients. Cancer 57:616-621, 1986
29. Wade DS, Nava HR, Douglass HO: Neutropenic enterocolitis - Clinical diagnosis and management. Cancer 69:17-23, 1992
30. Thaler M, Pastakia B, Shawker TH, et al: Hepatic candidiasis in cancer patients: The evolving picture of the syndrome. Ann Intern Med 108:88-100, 1988
31. Parrilli G, laffaioli RV, Capuano G, et al: Changes in intestinal permeability to lactulose induced by cytotoxic chemotherapy. Cancer Treat Rep 66:1435-1436, 1982
32. 51Cr-EDTA test for intestinal permeability. Lancet 2:38-39, 1984
33. Fegan C, Poynton CH, Whittaker JA: The gut mucosal barrier in bone marrow transplantation. Bone Marrow Transplant 5:373-377, 1990
34. Schimpff SC, Young VM, Greene WH: Origin of infection in acute nonlymphocytic leukemia: Significance of hospital acquisition of potential pathogens. Ann Intern Med 77:707-714, 1972
35. Tancrède CH, Andremont AO: Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 152:99-103, 1985
36. Wells CL, Maddaus MA, Simmons RL: Proposed mechanisms for translocation of intestinal bacteria. Rev Infect Dis 10:958-979, 1988
37. Donnelly JP, Muus P, Schattenberg A: A scheme for daily monitoring of oral mucositis in allogenic BMT recipients. Bone Marrow Transplant 9:409-413, 1992
38. Johnson EJ, MacGowan AP, Potter MN, et al: Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy. J Antimicrob Chemother 25:837-842, 1990
39. Lew MA, Kehoe K, Ritz J, et al: Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: A randomized, controlled trial. J Clin Oncol 13:239-250, 1995
40. Ward TT, Thomas RG, Fye CL, et al: Trimethoprim-sulfamethoxazole prophylaxis in granulocytopenic patients with acute leukemia: Evaluation of serum antibiotic levels in a randomized, double-blind, placebo-controlled Department of Veterans Affairs cooperative study. Clin Infect Dis 17:323-332, 1993